UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 8-K

______________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~June 74, 2026

10x Genomics, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-39035	45-5614458
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6230 Stoneridge Mall Road

Pleasanton, California 94588

(925) 401-7300

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

___________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol

Name of each exchange

on which registered

Class A common stock, par value $0.00001 per share

TXG

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.0207 ~~Results~~Submission of ~~Operations~~Matters ~~and~~to ~~Financial~~a ~~Condition.~~Vote of Security Holders

OnThe ~~May 7,~~annual ~~2026,~~meeting of stockholders of 10x Genomics, Inc. (the “"Company") was held on June 4, 2026 via live webcast (the “Annual Meeting”). ~~issued~~At athe ~~press~~Annual ~~release~~Meeting, ~~announcing~~there were present, virtually or by proxy, holders of 117,542,161 shares of the Company’'s ~~financial~~Class ~~results~~A ~~for~~and Class B common stock, representing 198,815,518, or approximately 90.5%, of the ~~quarter~~219,700,782 ~~ended~~eligible ~~March 31~~votes, ~~2026~~constituting a quorum. AThe ~~copy~~matters ofsubmitted to a vote at the ~~press~~Annual ~~release~~Meeting isand ~~attached~~the ~~hereto~~final asvoting ~~Exhibit~~results ~~99.1.~~of such matters were as follows:

~~The~~Proposal ~~information~~1 ~~furnished pursuant to Item 2.02 in this Current Report on Form 8~~-~~K and~~ ~~the~~Election ~~press release attached as Exhibit 99.1 hereto shall not be deemed “filed” for purposes~~ of ~~Section 18~~Directors of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

~~Item 9.01~~The ~~Financial~~Company’s ~~Statements~~stockholders approved the election of three Class I directors, each to hold office for a three-year term expiring at the Company’s 2029 annual meeting of stockholders or until his respective successor has been duly elected and ~~Exhibits~~qualified or until his earlier resignation or removal. The final voting results were as follows:

(d)Exhibits.


Nominee	Votes For	Votes Against	Abstentions	Broker Non-Votes
Serge Saxonov	164,137,381	15,559,860	557,329	18,560,948
Benjamin J. Hindson	162,942,766	16,761,532	550,270	18,560,950
John R. Stuelpnagel	155,628,365	24,072,179	554,023	18,560,951

Exhibit No.						Description of Exhibits
99.1						Press Release dated May 7, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

Proposal 2 - Ratification of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026. There were no broker non-votes on this proposal. The final voting results were as follows:


Votes For	Votes Against	Abstentions	Broker Non-Votes
197,719,939	458,231	637,346	—

Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers

The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as described in more detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 24, 2026. The final voting results were as follows:


Votes For	Votes Against	Abstentions	Broker Non-Votes
176,677,540	2,828,730	748,296	18,560,952

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	10x Genomics, Inc.
	By:	/s/ Randy Wu
	Name:	Randy Wu
	Title:	General Counsel and Secretary
Date: May 7, 2026
Date: June 8, 2026

Filing Compare · 10x Genomics, Inc.